A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02451982

Title field or adapter rule

{'original_value': 'A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.653893+00:00

Published At

2026-10-13T00:00:00+00:00

Record Updated At

2026-10-13

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-13", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT02451982"

protocolSection.identificationModule.officialTitle

"A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm A: CY/GVAX alone', 'Arm B: CY/GVAX with nivolumab', 'Arm C: CY/GVAX with nivolumab and urelumab'], 'description': '200 mg/m2 IV', 'name': 'Cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm A: CY/GVAX alone', 'Arm B: CY/GVAX with nivolumab', 'Arm C: CY/GVAX with nivolumab and urelumab'], 'description': '5x10\\^8 cells intradermal injection', 'name': 'GVAX pancreatic cancer', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm B: CY/GVAX with nivolumab', 'Arm C: CY/GVAX with nivolumab and urelumab', 'Arm D: BMS-986253 and Nivolumab'], 'description': '480 mg IV', 'name': 'Nivolumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm C: CY/GVAX with nivolumab and urelumab'], 'description': '8 mg IV', 'name': 'Urelumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm D: BMS-986253 and Nivolumab'], 'description': '2400 mg IV', 'name': 'BMS-986253', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Cyclophosphamide (protocolSection.armsInterventionsModule.interventions[].name)
• Nivolumab (protocolSection.armsInterventionsModule.interventions[].name)
• Urelumab (protocolSection.armsInterventionsModule.interventions[].name)
• BMS-986253 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.